UNSPSC 51363302: Methyprylon

This classification denotes a sedative and hypnotic with the molecular formula C10H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUT48I42ON, chemically known as 3,3-diethyl-5-methylpiperidine-2,4-dione but generally known as methyprylon, which bears US NIH Compound Identifier 4162. European Medicines Agency schedules Methyprylon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08879MIG.

UNSPSC 51363302 Methyprylon is a Commodity code that nominally covers a specific sedative-hypnotic pharmaceutical, but recent state and local solicitations under this code show little alignment with the product name itself. Instead, the opportunities reveal procurement focused on naloxone, safe drug deactivation systems, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and over-the-counter products — a broad and inconsistent set of health and pharmacy-related purchases that do not center on methyprylon. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities including Oregon). The mismatch between the code's nominal scope and actual procurement activity suggests either a tagging error in recent opportunities or a code that captures heterogeneous pharmaceutical and health-supply categories inconsistently across jurisdictions.

Geographic activity appears concentrated in the Southeast and Upper Midwest, with recent opportunities posted in Florida, Texas, and Minnesota as of mid-2026. Representative solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026, due July 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026, with immediate response deadline), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products serving multiple state and local jurisdictions (posted January 20, 2026, due March 26, 2026). Because the recent opportunities tagged under this code do not reflect methyprylon-specific procurement, business development professionals should verify the actual commodity codes under which their target pharmaceuticals or health supplies are solicited rather than relying on the code's nominal name.